Business

The TOBI Podhaler has been named a bronze winner in the General Hospital Devices and Therapeutics Products division of the Medical Design Excellence Awards presented by UBM Canon and MD+DI. The inhaler, which is marketed… Read more . . .

Mylan has announced that its subsidiary Mylan Specialty (formerly Dey Pharma) has reached an agreement with Sunovion Pharmaceuticals (formerly Sepracor) in which Sunovion “has acknowledged that two Mylan patents are valid, enforceable and infringed by… Read more . . .

“Under the ‘ordinary consumer’ standard, a product designed for intranasal use is expected not to cause irreparable injury to the nose if used in a foreseeable manner,” said U.S. District Judge William Alsup in his… Read more . . .

Swedish contract developer and manufacturer Recipharm says that it has borrowed €90 million from Swedbank AB in order to finance additional contract pharmaceutical manufacturing capacity and acquisitions. The company says that it also plans to… Read more . . .

Inhaled drug developer Prosonix has announced the second closing of its Series B equity financing round, which was extended to £17.1M. A new investor, Gimv, added £5.7M to the funds from original syndicate members Ventech,… Read more . . .

Pearl Therapeutics has won a 2012 TiE50 award from the Indus Entrepreneurs (TiE). Pearl was one of ten winners in the life sciences category. Pearl develops inhaled therapies based on its proprietary particle engineering technology.… Read more . . .

The US Patent and Trade Office has awarded a second patent, to Aegis Therapeutics for stabilized formulations of parathyroid hormone and parathyroid hormone analogs. The new patent (US Patent No. 8,173,594) covers formulations for both… Read more . . .

Rigel Pharmaceuticals says that it plans to focus its efforts on two inhaled asthma therapies: R343, an inhaled SYK inhibitor and R256, an inhaled IL13 signaling/JAK inhibitor. A Phase 2 clinical study of R343 will… Read more . . .